What investor type does AbbVie fit best in FoxScore?

AbbVie fits a more opportunity-seeking investor type in FoxScore: performance is the strongest sub-score. That suggests above-average historical returns — but check stability to ensure the performance wasn’t “paid for” with high volatility or deep drawdowns.

How meaningful is the available history for AbbVie?

AbbVie currently has about 13.1 years of price history since it started trading. That’s a solid base to interpret returns, drawdowns and trend behavior since launch — earlier market crises happened before the asset existed and are therefore not part of its history.

What is FoxScore good for — and what is it not for?

FoxScore is an analysis and comparison tool: it helps you sort assets quickly, compare profiles and spot strengths/weaknesses. It’s not a substitute for your own research or fundamental analysis, and it’s not a buy/sell recommendation.

Analysis for AbbVie

ABBV · As of: 02/17/2026

Basic information

Type: Stock

Region: US

Sector: Health Care

TER: –

History

Available history:13.1 years

Last tradingday:02/17/2026

Description & usage

AbbVie is a pharmaceutical company focused on immunology, oncology, and neuroscience, with an additional medical aesthetics business. Revenue comes from sales of prescription medicines and select aesthetics products. Customers include healthcare systems, clinicians, and patients worldwide, with strong US exposure.

Scale: 0 = weak, 50 = average, 100 = top

Analysis summary

AbbVie (ABBV) currently has a total score of 63 points, placing it in the strong range. The score is made up of Performance (73), Stability (56) and Trend (47). The profile is clearly uneven: Performance stands out while Trend is more neutral.

Performance scores 73 points (strong). Key strength: 5Y return at 120.1 %. Even the weakest return is still strong in absolute terms: 1Y return at 19.9 %.

Stability scores 56 points (neutral). Best-ranked metric: max drawdown (5Y) at -24.3 %. Weaker metric: Sharpe ratio (90d) at -0.02. Higher Stability points are better and typically reflect calmer swings and smaller drawdowns—but prices can still fall.

Trend scores 47 points (neutral). Most supportive signal: Price is about 10.1 % above SMA200. Weaker metric: trend strength at -0.36. That often means the move is strong, but not perfectly steady.

Overall, the profile has a clear strength in Performance, while Trend is the main limiter. On a metric level, max drawdown (5Y) stands out, while trend strength is the main weak spot.

(Historical evaluation, not investment advice.)

Chart anzeigen

Wenn du fortfährst, wird der Chart von TradingView geladen. Dabei können Daten (z. B. deine IP-Adresse) an TradingView übertragen werden.

Overall score

strong

Scores

Metrics

FAQ

What investor type does AbbVie fit best in FoxScore?: AbbVie fits a more opportunity-seeking investor type in FoxScore: performance is the strongest sub-score. That suggests above-average historical returns — but check stability to ensure the performance wasn’t “paid for” with high volatility or deep drawdowns.
How meaningful is the available history for AbbVie?: AbbVie currently has about 13.1 years of price history since it started trading. That’s a solid base to interpret returns, drawdowns and trend behavior since launch — earlier market crises happened before the asset existed and are therefore not part of its history.
What is FoxScore good for — and what is it not for?: FoxScore is an analysis and comparison tool: it helps you sort assets quickly, compare profiles and spot strengths/weaknesses. It’s not a substitute for your own research or fundamental analysis, and it’s not a buy/sell recommendation.